COMMUNIQUÉS West-GlobeNewswire

6 Best Fat Burners For Women: Top Over the Counter and Online Pills and Fat Burning Supplements For Women Weight Loss In 2025 - Wolfson Brands
10/05/2025
Discover the 6 best fat burners for women in 2025. Top OTC & online weight loss pills from Wolfson Brands (UK) Limited to burn fat, boost energy & crush cravings fast. New York City, NY, May 10, 2025 (GLOBE [...]
Best Fat Burners For Men 2025: Top Weight Loss Pills & Supplements For Fast Fat Loss - Wolfson Brands Ltd
10/05/2025
Discover the best fat burners for men in 2025! Our expert guide ranks the top weight loss pills and supplements that deliver fast fat loss and shredded results. Find out which fat burners work and how to get the body [...]
4 Best Supplements for Muscle Growth in 2025 - Legal Steroid Alternatives & Bodybuilding Supplements for Bulking and Strength - Wolfson Brands
10/05/2025
Glasgow, May 10, 2025 (GLOBE NEWSWIRE) -- The best legal supplements for muscle growth is presented by Wolfson Brands Building serious muscle isn’t just about hitting the gym hard, it’s about giving your body the right [...]
Activists Mark Luigi Mangione’s Birthday With Aerial Protest as Times Square Billboard on Jury Rights Explodes Online
10/05/2025
Two independent campaigns in NYC spotlight healthcare and legal reform amid public outcry over Luigi Mangione’s case. Image by POPNYC NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Two major public actions are unfolding in [...]
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
09/05/2025
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current [...]
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
09/05/2025
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension NEW YORK, [...]
HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferences
09/05/2025
DRAPER, Utah, May 09, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its [...]
Coave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases
09/05/2025
New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following intra-cerebrospinal fluid [...]
Publication relating to transparency notifications
09/05/2025
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 9, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure [...]
Publication relative à des notifications de transparence
09/05/2025
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 9 mai 2025 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la [...]
Olema Oncology to Participate in Upcoming Investor Conferences
09/05/2025
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/05/2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
09/05/2025
SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
09/05/2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/05/2025
MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Oculis Publishes Invitation to the Annual General Meeting
09/05/2025
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at [...]
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
09/05/2025
- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months - Initiated utilization of share repurchase program - Cash [...]
Oculis Publishes Invitation to the Annual General Meeting
09/05/2025
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at [...]
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
09/05/2025
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for [...]

Pages